This guideline covers the assessment and care of adults who are at risk of or who have cardiovascular disease (CVD), such as heart disease and stroke. It aims to help healthcare professionals identify people who are at risk of cardiovascular problems. including people with type 1 or type 2 diabetes, or chronic kidney disease. It describes the lifestyle changes people can make and how statins can be used to reduce their risk.
In September 2016, recommendation 1.3.28 was amended to clarify what was meant by high-intensity statin treatment, and that the recommendation applies to both primary and secondary prevention. The term ‘high-intensity statin’ was also added to the ‘Terms used in this guideline’ section and linked to throughout.
This guideline includes recommendations on:
Who is it for?
- Healthcare professionals
- People who are at risk of CVD or who have had CVD
Guideline development process
This guideline updates and replaces NICE guideline CG67 (September 2008) and technology appraisal guidance TA94 (January 2006).
Next review date: 2018
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.